SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

DIAMOND The Cat Coin ($DMTC.X) is gaining attention as traders discuss its potential for a significant surge, pointing to chart signals and strong buy walls. The community emphasizes accumulating positions, suggesting a "quiet before the storm" scenario, with many referencing "rocket" and "moon" analogies implying strong upward momentum. Some users are warning of a potential rug pull.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis (AVNT.X) is trending as community members discuss its recent price surge and potential for further growth, with some drawing comparisons to other successful tokens. Attention is focused on its backers and potential for trading real-world assets, while others are speculating about near-term price targets. The community highlights that it is a top gainer on Coinbase.

Hecla Mining Co. engages in the provision of precious and base metals. It operates through the following segments: Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Other. The company was founded by Amasa B. Campbell, Patsy Clark, and John Finch on October 14, 1891 and is headquartered in Coeur d'Alene, ID.

Hecla Mining Co.

Hecla Mining is trending as discussions revolve around the potential impact of rising silver and gold prices on the company. Community members are also actively discussing Hecla's inclusion in the S&P SmallCap 600 index, which may lead to increased passive investment flows. Broader positive sentiment in the materials sector is also seen as a potential tailwind for the stock.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies behind its Bitcoin-native status and fair distribution, contrasting it with other meme coins. The community emphasizes its strong foundation and potential for significant growth as the leading meme coin on the Bitcoin blockchain. Discussions highlight the mission to onboard millions to Bitcoin through a decentralized, community-driven approach.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

Binance's BNB.X is currently trending as the crypto community discusses its impressive rally and potential targets, including speculation about reaching $1000 soon. The recent partnership between Binance and Franklin Templeton to develop digital asset initiatives has also generated significant buzz. Discussions also involve the potential for Solana to surpass BNB.X in market capitalization.

Pump.fun

$PUMP.X is trending as the community highlights its position as a key player in the Solana meme coin ecosystem, with many pointing to the project's continued buybacks. Community members are actively discussing potential price targets and expressing excitement about its potential for significant gains in the current cycle. Some are calling it the 'NASDAQ of shit coins' and believe it will lead the altcoin season.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health ($HROW) is trending as investors discuss the potential impact of VEVYE's growth and upcoming catalysts like the investor day and Q3 report. The community is debating VEVYE's market position amid mixed patient reviews of Tryptyr, another dry eye treatment. Some are optimistic about potential acquisitions and the company's long-term growth prospects, while others focus on short interest and technical analysis.

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on the development and manufacturing of genetic medicines to treat both inherited and more common conditions with severe unmet need. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc

MeiraGTx (MGTX) is trending following news of a strategic investment from Sanofi, with the community viewing this as a strong signal of confidence in the company's gene therapy platform and pipeline. Discussions revolve around potential implications for future partnerships, acquisitions, and the undervalued nature of MGTX relative to its assets. Optimism is fueled by upcoming catalysts and the potential for significant revenue growth.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as community members discuss potential organized attacks from bears and debate the company's prospects relative to Joby Aviation. Positive catalysts mentioned include the White House's eVTOL pilot program and potential military contracts, while some express concern over a lack of updates from the company. Discussions also include technical analysis, short interest, and institutional investment.

Direxion Shares ETF Trust - Direxion Daily Gold Miners Index Bull 2X Shares

Direxion Daily Gold Miners Index Bull 2X Shares

NUGT is trending due to bullish sentiment surrounding gold miners, potentially fueled by anticipation of central bank rate cuts and ongoing geopolitical uncertainty. The community is actively discussing gold's potential as a safe-haven asset amid market instability, with some analysts predicting further price increases. Some traders are highlighting technical patterns suggesting potential breakout opportunities, while others remain cautious, pointing to overbought conditions and potential pullbacks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and extended gains after-hours after the company said it was exploring strategic alternatives.&nbsp;The cancer drug developer said its options included a merger, acquisition, partnership, or licensing deal to advance its pipeline and maximize shareholder value.&nbsp;The company has retained MTS Health Partners to assist with the process.CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat showing a six-month survival benefit in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.&nbsp;However, Brady said capital markets "have been unavailable to support the next stage of advancement."On Stocktwits, sentiment for Tempest surged into the 'extremely bullish' zone from 'neutral' a day ago, accompanied by message volume soaring over 135% in the 24 hours to late Wednesday.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TPST_sentiment_and_message_volume_April_9_png_4939200400.webp" alt="TPST sentiment and message volume April 9.png" width="1318" height="316"><figcaption>TPST sentiment and message volume April 9. | source: Stocktwits</figcaption></figure>One user said the CEO was "soliciting bidders" through this move following the recent 1-for-13 reverse stock split."Poison pill is still at $25. Now, anyone who wants more than a 10 percent ownership stake can buy whatever they want at $25 or more. Well played, Mr. Brady!" they wrote.<stembedurl>https://stocktwits.com/xyz1232/message/611152790</stembedurl>Another pinned hopes on "well-known" MTS Partners fetching a good merger deal for Tempest. "Even If TPST gets a below-average deal at $360 million, we're still looking at $100 per share."<stembedurl>https://stocktwits.com/GreylockSec/message/611168891</stembedurl>Amezalpat, Tempest's lead candidate, has received both Orphan Drug and Fast Track designations from the FDA.&nbsp;TPST-1495, a dual EP2/EP4 antagonist, is also advancing toward a Phase 2 trial in familial adenomatous polyposis (FAP) with NCI support.<a href="https://stocktwits.com/symbol/TPST">Tempest Therapeutics stock</a> has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger

CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 

Equity

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Glancy Prongay & Murray LLP (GPM) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors and officers possible violations of state laws. If...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data...

Tempest Therapeutics, Inc. (NASDAQ:TPST) Expected to Post Q1 2024 Earnings of ($0.36) Per Share

Tempest Therapeutics, Inc. (NASDAQ:TPST  Free Report)  HC Wainwright issued their Q1 2024 earnings estimates for Tempest Therapeutics in a report released on Wednesday, March 20th...

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright

Tempest Therapeutics (NASDAQ:TPST  Get Free Report)s stock had its buy rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday...

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by William Blair

Tempest Therapeutics (NASDAQ:TPST  Get Free Report)s stock had its outperform rating restated by investment analysts at William Blair in a note issued to investors on...

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two...

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$3.27	--	--	N/A
Q2 '25	-$3.23	-$2.07	35.91%	BEAT
Q1 '25	-$3.29	-$3.16	4.05%	BEAT
Q4 '24	-$0.25	-$4.03	-1500.10%	MISSED
Q3 '24	-$0.36	-$0.41	-13.26%	MISSED

TPST
Tempest Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest TPST News

TPST Tempest Therapeutics Inc